Helen Torley Sells 10,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $63.50, for a total value of $635,000.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $48,754,030. The trade was a 1.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00.
• On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total value of $702,100.00.
• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.69, for a total value of $1,393,800.00.
• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $78.64, for a total value of $786,400.00.
• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00.

Halozyme Therapeutics Stock Up 2.9%

Halozyme Therapeutics stock opened at $65.43 on Thursday. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $82.22. The stock’s fifty day simple moving average is $69.52 and its 200-day simple moving average is $69.07. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The firm has a market capitalization of $7.75 billion, a P/E ratio of 26.28, a P/E/G ratio of 0.26 and a beta of 1.03.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. During the same period in the prior year, the company posted $1.26 EPS. The firm’s revenue was up 51.6% compared to the same quarter last year. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Halozyme struck a global exclusive collaboration and license with Vertex to use Hypercon™ (covers up to three targets). The deal positions Halozyme’s Hypercon (and related Elektrofi capability reported in coverage) for near‑term partnering revenue and broader commercial adoption. Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
• Neutral Sentiment: CEO Helen Torley sold 10,000 shares on April 6 at an average price of $63.50 under a pre‑arranged Rule 10b5‑1 plan; her ownership declined ~1.29% as reported. The trade is disclosed to the SEC and appears part of an ongoing programmed sale cadence. Insider Selling: Halozyme Therapeutics CEO Sells 10,000 Shares
• Neutral Sentiment: Analysts maintain a mixed view: consensus rating is “Hold” with a consensus price target notably above current levels. That keeps upward expectations moderated despite the Vertex deal. Halozyme Receives Consensus Recommendation of “Hold” from Analysts
• Neutral Sentiment: Institutional ownership is high (~98%) with only modest position changes reported; this suggests limited near‑term volatility from large fund rebalancing but does concentrate conviction among major holders. MarketBeat HALO profile

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently bought and sold shares of HALO. Root Financial Partners LLC acquired a new position in Halozyme Therapeutics in the third quarter valued at $25,000. Measured Wealth Private Client Group LLC boosted its stake in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC boosted its stake in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares in the last quarter. Richardson Financial Services Inc. boosted its stake in Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 198 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in Halozyme Therapeutics in the second quarter valued at $32,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on HALO shares. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Benchmark boosted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Hold” and an average target price of $78.56.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.